Wannee Kantasiripitak
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's Disease.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: April 15, 2025
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis.
Journal: British journal of clinical pharmacology
Published: February 07, 2025
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
Journal: Journal of Crohn's & colitis
Published: January 20, 2023
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 08, 2022
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases.
Journal: Expert review of clinical pharmacology
Published: January 17, 2022
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.
Journal: British journal of clinical pharmacology
Published: October 30, 2020
Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
Journal: Frontiers in pharmacology
Published: February 13, 2020
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
Journal: Inflammatory bowel diseases
Published: March 27, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026